THIRD AMENDMENT OF LEASELease • August 8th, 2008 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
THIS THIRD AMENDMENT OF LEASE (this “Amendment”) is made as of the 23rd day of April, 2008 (the “Effective Date”), by TBCI, LLC, a Massachusetts limited liability company, as successor to BHX, LLC, as Trustee of 3 Forbes Realty Trust, a Massachusetts nominee trust (“Landlord”), and ANTIGENICS, INC., a Delaware corporation (“Tenant”).
Amendment to Exhibit A-5 to Master Services AgreementAntigenics Inc /De/ • August 8th, 2008 • Biological products, (no disgnostic substances)
THE UNDERSIGNED HEREBY ACKNOWLEDGE AND AGREE THAT THIS AMENDMENT TO EXHIBIT A-5 IS INCORPORATED BY REFERENCE INTO, AND SUBJECT TO THE PROVISIONS OF THAT CERTAIN MASTER SERVICES AGREEMENT BETWEEN THE PARTIES DATED MAY 24, 2007, AS AMENDED (THE “AGREEMENT”).
AMENDMENT NO. 8 TO THE PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • August 8th, 2008 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
This AMENDMENT NO. 8 (“AMENDMENT NO. 8”) to the ORIGINAL LICENSE (as defined below) effective this 4th day of April, 2008 (“AMENDMENT NO. 8 EFFECTIVE DATE”) is made by and between the BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, a component institution of SYSTEM), and ARONEX PHARMACEUTICALS, INC., a Delaware corporation having a principal place of business located at 3 Forbes Road, Lexington, Massachusetts 02421 (“LICENSEE”), a wholly-owned subsidiary of ANTIGENICS INC., a Delaware corporation. BOARD and LICENSEE may be referred to hereafter collectively as the “PARTIES.” Capitalized terms not defined herein shall have the meaning set forth in the ORIGINAL LICENSE.
